沙巴托利单抗联合去甲基化药物一线治疗较高危骨髓增生异常综合征(STIMULUS-MDS1):一项随机、双盲、安慰剂对照的2期试验
STIMULUS-MDS1是一项在17个国家54个中心开展的随机双盲安慰剂对照2期试验,纳入127例初治的较高危骨髓增生异常综合征患者,比较沙巴托利单抗联合去甲基化药物与安慰剂联合去甲基化药物的疗效与安全性。主要终点完全缓解率和无进展生存期均未达到,沙巴托利单抗组完全缓解14/65(22%)vs 安慰剂组11/62(18%)(p=0.77),中位无进展生存期11.1个月 vs 8.5个月(HR 0.75,95%CI 0.48-1.17;p=0.1022)。沙巴托利单抗在多数患者中安全性可控,一项评估总生存获益的3期随机试验正在进行。
要点
- 沙巴托利单抗联合去甲基化药物未显著改善完全缓解率:22% vs 18%(p=0.77)。
- 中位无进展生存期11.1个月 vs 8.5个月(HR 0.75,95%CI 0.48-1.17;p=0.1022),未达统计学显著。
- 沙巴托利单抗组发生1例治疗相关死亡(肺炎)和1例严重潜在治疗相关免疫介导不良事件。
核心结论
- 在初治较高危骨髓增生异常综合征患者中,沙巴托利单抗联合去甲基化药物未显著改善完全缓解率或无进展生存期。
- 沙巴托利单抗在多数较高危骨髓增生异常综合征患者中安全性可控。
- 一项随机3期试验正在进行,以评估沙巴托利单抗联合阿扎胞苷在该 setting 中对总生存的潜在获益。
研究设计与样本
- STIMULUS-MDS1是一项在17个国家54个研究中心开展的多中心、随机、双盲、安慰剂对照2期研究。
- 纳入年龄≥18岁、按修订版国际预后评分系统(IPSS-R)为中危、高危和极高危、既往未接受治疗的骨髓增生异常综合征成人患者。
- 患者按1:1随机分配至静脉沙巴托利单抗(第8天和第22天400 mg)或安慰剂联合去甲基化药物(静脉地西他滨第1-5天20 mg/m2,或静脉或皮下阿扎胞苷第1-7天或第1-5天和第8-9天75 mg/m2),每28天为一周期直至治疗终止。
- 两个主要终点为完全缓解率和无进展生存期,在全部随机分配患者的全分析集中评估。
- 2019年7月29日至2020年8月10日共随机分配127例患者:沙巴托利单抗组65例,安慰剂组62例;中位年龄73岁(IQR 69-77),男性86/127例(68%),白人77/127例(61%)。
主要发现
- 主要终点未达到。
- 完全缓解(截止日期2021年3月10日):沙巴托利单抗组14/65例(22%;95%CI 12.3-33.5)vs 安慰剂组11/62例(18%;95%CI 9.2-29.5)(p=0.77)。
- 最终分析截止日期(2022年3月1日)时,无进展生存期中位随访:沙巴托利单抗组17.8个月(IQR 16.6-19.4)vs 安慰剂组19.2个月(IQR 17.7-22.3)。
- 中位无进展生存期:沙巴托利单抗组11.1个月(95%CI 7.6-17.6)vs 安慰剂组8.5个月(95%CI 6.9-11.3)(HR 0.75,95%CI 0.48-1.17;p=0.1022)。
- 任何级别最常见不良事件:中性粒细胞减少(沙巴托利单抗组35/62例[56%] vs 安慰剂组43/63例[68%])、血小板减少(30/62例[48%] vs 32/63例[51%])、便秘(29/62例[47%] vs 24/63例[38%])、腹泻(27/62例[44%] vs 14/63例[22%])、贫血(22/62例[35%] vs 34/63例[54%])、发热性中性粒细胞减少(22/62例[35%] vs 15/63例[24%])、白细胞减少(15/62例[24%] vs 20/63例[32%])。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sabatolimab is an immunotherapy targeting T-cell immunoglobulin domain and mucin domain-3 (TIM-3), an immuno-myeloid regulator expressed on immune cells and leukaemic stem cells. In this trial, we compared the efficacy and safety of sabatolimab plus hypomethylating agent with placebo plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes. METHODS: STIMULUS-MDS1 was a multicentre, randomised, double-blind, placebo-controlled, phase 2 study done at 54 investigational sites in 17 countries. Adult patients (aged ≥18 years) with intermediate-risk, high-risk, and very high-risk myelodysplastic syndromes (according to Revised International Prognostic Scoring System criteria) who had not received previous treatment were included. Patients were randomly assigned (1:1) to intravenous sabatolimab (400 mg on day 8 and 22) or placebo plus a hypomethylating agent (intravenous decitabine 20 mg/m2 on day 1-5 or intravenous or subcutaneous azacitidine 75 mg/m2 on day 1-7 or day 1-5 and day 8 and 9) every 28 days until treatment discontinuation. The two primary endpoints were complete response rate and progression-free survival, assessed in the full analysis set, which included all randomly assigned patients. Complete response was analysed, as prespecified, 7 months after the last patient was randomly assigned. All other analyses presented, including progression-free survival, were done at the final data cutoff prespecified via a protocol amendment on Sept 2, 2021. Safety was assessed in in all patients who received at least one dose of study treatment. This study is registered with ClinicalTrials.gov, NCT03946670, and is ongoing. FINDINGS: Between July 29, 2019, and Aug 10, 2020, 127 patients were randomly assigned to sabatolimab plus a hypomethylating agent group (sabatolimab group; n=65) or placebo plus a hypomethylating agent (placebo group; n=62). The median age of participants was 73 years (IQR 69-77), of whom 86 (68%) of 127 patients were male and 77 (61%) were White. The primary endpoints were not met. Complete response (cutoff date of March 10, 2021) was achieved in 14 (22%; 95% CI 12·3-33·5) of 65 patients in the sabatolimab group vs 11 (18%; 9·2-29·5) of 62 patients in the placebo group (p=0·77). At the cutoff date of the final analysis (March 1, 2022), median follow-up for progression-free survival was 17·8 months (IQR 16·6-19·4) in the sabatolimab group and 19·2 months (17·7-22·3) in the placebo group, and the median progression-free survival was 11·1 months (95% CI 7·6-17·6) in the sabatolimab group vs 8·5 months (6·9-11·3) in the placebo group (hazard ratio 0·75 [95% CI 0·48-1·17]; p=0·1022). The most common adverse events of any grade were neutropenia (35 [56%] of 62 patients in the sabatolimab group vs 43 [68%] of 63 patients in the placebo group), thrombocytopenia (30 [48%] vs 32 [51%]), constipation (29 [47%] vs 24 [38%]), diarrhoea (27 [44%] vs 14 [22%]), anaemia (22 [35%] vs 34 [54%]), febrile neutropenia (22 [35%] vs 15 [24%]), and leukopenia (15 [24%] vs 20 [32%]). One patient developed a serious potential treatment-related immune-mediated adverse event in the sabatolimab group. There was one treatment-related death in the sabatolimab group due to pneumonitis. INTERPRETATION: The addition of sabatolimab to hypomethylating agents in this study did not result in a significant improvement in complete response rates or progression-free survival. Sabatolimab had a manageable safety in most patients with higher-risk myelodysplastic syndromes. A randomised phase 3 trial is ongoing to assess the potential benefit of sabatolimab plus azacitidine on overall survival in this setting. FUNDING: Novartis Pharmaceuticals.
引用
- Zeidan AM, Ando K, Rauzy O, et al. Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2023. PMID: 38065203. doi:10.1016/S2352-3026(23)00333-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。